The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes

To Evaluate the Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes in Both GnRH Agonist and GnRH Antagonist Treated Ovarian Stimulation Protocols

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02114645

Enrollment

100

Registered

2014-04-15

Start date

2014-04-30

Completion date

2015-04-30

Last updated

2014-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

Luteal phase support,GnRH agonist,ART cycles

Brief summary

Detailed description

This prospective clinical trial evaluates the effect of a two dose GnRH agonist administered in the luteal phase on the outcome of ART cycles stimulated with the long GnRH agonist and GnRH antagonist protocol. Decision between each of these two protocols was subjective and depended on the clinical context.In addition to routine luteal phase support with progesterone and estradiol valerate,women received two dose of GnRH agonist on the fifth and tenth day after ET.Live birth rate was the primary outcome measure.

Interventions

DRUGLeuprolide acetate

in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate is given subcutaneously as luteal phase support

DRUGvaginal progesterone

crinone gel is applied till fetal heart beat is detected

DRUG4 mg oral estradiol valerate

estrofem is given twice a day

Study design

Allocation

NON_RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 38 Years

Healthy volunteers

Yes

Inclusion criteria

* Couples undergoing ART with their own gametes. * Couples having at least one good embryo available for transfer. * Normoresponder * Infertility etiology is unexplained * ovulation triggered by intramuscular injection of 10000 IU of HCG

Exclusion criteria

Patients older than 38 years old * High and poor responder patients

Design outcomes

Primary

Measure	Time frame
Live Birth Rate	42 weeks

Secondary

Measure	Time frame
Ongoing pregnancy	more than 20 weeks
miscarriage	up to 20 weeks
OHSS	up to 10 weeks

Countries

Turkey (Türkiye)

Contacts

Primary ContactNagihan Cengaver, MD

nagihancengaver@gmail.com+905556309298

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026